Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Avutometinib with Defactinib for the Treatment of Patients with Metastatic Diffuse Gastric Cancer

Trial Status: active

This phase II trial tests how well avutometinib and defactinib work in treating patients with diffuse gastric cancer that that has spread from where it first started (primary site) to other places in the body (metastatic). Avutometinib and defactinib are in a class of medications called kinase inhibitors. They may kill or stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving avutometinib with defactinib may kill more tumor cells in patients with metastatic diffuse gastric cancer.